Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mGluR5 negative allosteric modulator
- Development stage
- Preclinical
- Lead developer
- Hua Medicine
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Oral, Intravenous, Subcutaneous
01
Overview
mGluR5 negative allosteric modulator is a small molecule drug candidate being developed by Hua Medicine. It functions as a negative allosteric modulator (NAM) of the metabotropic glutamate receptor 5 (mGluR5), a G protein-coupled receptor that plays a key role in modulating excitatory neurotransmission in the central nervous system. The drug is primarily targeted for the treatment of Parkinson's Disease Levodopa-Induced Dyskinesia (PD-LID) and drug addiction. By acting as a negative allosteric modulator, the compound binds to a site distinct from the orthosteric glutamate binding site to reduce receptor activity. This mechanism is intended to alleviate the motor complications associated with long-term levodopa therapy in Parkinson's patients and to modulate the neurobiological pathways involved in substance use disorders.
- Other names
- mGluR5 negative allosteric modulatormGluR-5 negative allosteric modulatormGluR 5 negative allosteric modulator
02
Targets
GRM5 (Metabotropic glutamate receptor 5)
Beyond the preview
Go deeper on mGluR5 negative allosteric modulator.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mGluR5 negative allosteric modulator.